PSN
salicylic acid 1.5 % Topical Cream
Prescribable Name
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.
Proactiv Redness Correcting Treatment Cream
RxNorm Crosswalk NDC 11410-219
View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC
RxNorm Mapping Clinical Concepts
The product Proactiv Redness Correcting Treatment (NDC 11410-219) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 248609). By anchoring Alchemee, Llc's product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.
The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).
SCD
Featured Concept
salicylic acid 15 MG/ML Topical Cream
(RxCUI 248609)
Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
Understanding RxNorm Mapping for Proactiv Redness Correcting Treatment
RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 11410-219 to RxCUI 248609, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.
Term Type (TTY) Legend for This Page
The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:
- PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
- SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
- SY Synonym: An alternative clinical name or alias provided for search and retrieval clarity.
* Please review the full disclaimer at the bottom of this page.
